The inhibin/activin family and ovarian cancer

Trends in Endocrinology and Metabolism

Volumn 7, Issue 6, 1996, Pages 197-202

  Burger, Henry G ^a   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; INHIBIN; TUMOR MARKER;

CANCER CLASSIFICATION; EARLY DIAGNOSIS; GRANULOSA CELL TUMOR; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION;

EID: 0030217988     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/1043-2760(96)00107-5     Document Type: Article

References (41)

1. Bourne HR, Goretzki P, Landis C, et al.: 1991. G-protein oncogenes. In Brugge J, ed. Origins of Human Cancer: A Comprehensive Review. Plainview, NY, Cold Spring Harbor Laboratory Press, pp 327-333.
2. Burger HG: 1992. Inhibin. Reprod Med Rev 1:1-20.
3. Burger HG: 1993. Clinical review: clinical utility of inhibin measurements. J Clin Endocrinol Metab 76:1391-1396.
4. Burger HG, Robertson DM, Cahir N, et al.: 1996. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumors. Clin Endocrinol (Oxf) 44:413-418.
5. Cooke I, O'Brien M, Charnock FM, Groome NP, et al.: 1995. Inhibin as a marker for ovarian cancer. Br J Cancer 71:1046-1050.
6. Corrigan AZ, Bilezikjian LM, Carroll RS, et al.: 1991. Evidence for an autocrine role of activin B within rat anterior pituitary cultures. Endocrinology 128:1682-1684.
7. Demura T, Suzuki T, Tajima S, et al.: 1992. Competitive protein binding assay for activin A/EDF using follistatin determination of activin levels in human plasma. Biochem Biophys Res Commun 185:1148-1154.
8. Di Saia PJ, Creasman WT: 1993. Clinical Gynecologic Oncology, 4th ed. Epithelial Ovarian Cancer, Mosby Year Book, St Louis, pp 333-425.
9. Graves PE, Surwit EA, Davis JR, Stouffer RL: 1985. Adenylate cyclase in human ovarian cancers: sensitivity to gonadotropins and nonhormonal activators. Am J Obstet Gynecol 153:877-882.
10. Groome NP, Illingworth PJ, O'Brien M, et al.: 1994. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf) 40:717-723.
11. Groome NP, Illingworth PJ, O'Brien M, et al.: 1995. Quantification of inhibin Pro-α-C-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 80: 2926-2932.
12. Gurusinghe CJ, Healy DL, Jobling T, et al.: 1995. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 57:27-32.
13. Gustafson ML, Lee MM, Scully RE, et al.: 1992. Mullerian inhibiting substance as a marker for ovarian sex-cord tumour. N Engl J Med 326:466-471.
14. Healy DL, Burger HG, Mamers P, et al.: 1993. Inhibin: a serum marker for mucinous ovarian cancers. N Engl J Med 329:1539-1542.
15. Jacobs I: 1994. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Gynecol Oncol 55:S22-S27.
16. Jobling T, Mamers P, Healy DL, et al.: 1994. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55:285-289.
17. Kauppila A, Bangah M, Burger HG, Martikainen H: 1992. GnRH agonist therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol 6:271-274.
18. Knight PG, Muttukrishna S, Groome NP: 1996. Development and application of a two-site enzyme immunoassay for the determination of "total" activin-A concentrations in serum and follicular fluid. J Endocrinol 148:267-279.
19. Lappohn RE, Burger HG, Bouma J, et al.: 1989. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 321:790-793.
20. Lopez-Bernal A, Bellinger J, Marshall JM, et al.: 1995. G protein expression and second messenger formation in human granulosa cells. J Reprod Fertil 104:77-83.
21. Lyons J, Landis CA, Harsh G, et al.: 1990. Two G protein oncogenes in human endocrine tumors. Science 249:655-659.
22. Mather JP, Attie KM, Woodruff TK, et al.: 1990. Activin stimulates spermatogonial proliferation in germ-Sertoli cell co-cultures from immature rat testis. Endocrinology 127:3206-3214.
23. Matzuk MM, Finegold MK, Su JG, et al.: 1992. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360: 313-319.
24. Matzuk MM, Finegold MJ, Mather JP, et al.: 1994. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91: 8817-8821.
25. Merajver SD, Pham TM, Caduff RF, et al.: 1995. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet 9:439-443.
26. NIH Consensus Development Panel on Ovarian Cancer: 1995. Ovarian Cancer: screening, treatment or follow-up. JAMA 273:491-497.
27. Ozols, RF: 1994. Research directions in epithelial ovarian cancer. Gynecol Oncol 55:168-173.
28. Petraglia F, Gallinelli A, DeVita D, et al.: 1994. Activin at parturition: changes of maternal serum levels and evidence of binding sites in placenta and fetal membranes. Obstet Gynecol 84:278-282.
29. Poncelet E, Eliard P: 1990. Construction of a sensitive two-site imrnunoenzymatic assay for human inhibin in serum and other biological fluids. Hum Reprod 5:110-111.
30. Reincke M, Karl M, Travis W, Chrousos GP: 1993. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 77:1419-1422.
31. Risma KA, Clay CM, Nett TM, et al.: 1995. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA 92:1322-1326.
32. Robertson DM, Sullivan J, Watson M: 1995. Inhibin forms in human plasma, J Endocrinol 144:261-269.
33. Robertson DM, Burger HG, Sullivan J, et al.: 1996. Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab 81:669-676.
34. Russell P, Bannatyne P: 1989. Surgical Pathology of the Ovaries. Edinburgh, Churchill Livingstone.
35. Sheridan E, Silcocks P, Smith J, et al.: 1994. P53 mutation in a series of epithelial ovarian cancers from the United Kingdom, and its prognostic significance. Eur J Cancer 30A; 1701-1704.
36. Shikone T, Matzuk MM, Perlas E, Finegold MJ: 1994. Characterization of gonadal sex cordstromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol 8:983-995.
37. Sluijmer AV, Heineman MJ, Evers JLH, de Jong FH: 1993. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a post-menopausal patient with a granulosa cell tumour. Acta Endocrinol (Copenh) 12:311-314.
38. Spencer SJ, Rabinovici J, Jaffe RB: 1990. Human recombinant activin-A inhibits proliferation of human fetal adrenal cells in vitro. J Clin Endocrinol Metab 71:1678-1680.
39. Stouffer RL, Grodin MS, Davis JR, Surwit EA: 1984. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 59:441-446.
40. Vale W, Rivier C, Hsueh A, et al.: 1988. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44:1-34.
41. Weinstein LS, Shenker A, Gejman PV, et al.: 1991. Activating mutations of the stimulatory G-protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695.